The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens

Artac M., Bozcuk H., PEHLİVAN S., Akcan S., PEHLİVAN M., Sever T., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.136, sa.6, ss.803-809, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 136 Sayı: 6
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1007/s00432-009-0720-3
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.803-809
  • Anahtar Kelimeler: Colorectal cancer, Irinotecan, XPD, XRCC1, Single nucleotide polymorphisms, Overall survival, MULTIVARIATE-ANALYSIS, STRAND BREAKS, CANCER, CHEMOTHERAPY, GENE, REPAIR, CAPECITABINE, OXALIPLATIN, COMBINATION, TOXICITY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC).